Project R-16349

Modular Cell-Derived Nanoparticles: An Innovative Therapy for Ischemic Stroke (Research)

Ischemic stroke is a major neurological condition caused by an abrupt interruption of cerebral blood flow. It remains a leading cause of mortality and long-term disability worldwide, yet current therapeutic options are effective for only a limited subset of patients. This highlights a critical need for novel, broadly applicable interventions. Cell-derived nanotherapeutics have emerged as a promising alternative due to their scalability and translational potential. This project focuses on developing a regenerative nanoparticle platform derived from stem cells. We will assess their influence on immune responses and angiogenesis using established in vitro assays, followed by evaluation in a relevant preclinical stroke model. The outcomes of this work will advance understanding of stem cell–derived nanotherapeutics and lay the groundwork for future translational development.

01 December 2025 - 31 December 2028